Resources

Our resources include slide sets from presentations, webinars, congresses, videos of expert opinions, infographics and podcasts.

ViiV Exchange Videos
Resources

Videos and Recordings

View videos

ViiV Exchange Infographics
Resources

Infographics

View Infographics

ViiV Exchange Slide Sets
Resources

Slide Sets

View Slide Sets

Podcasts
RESOURCES

Podcasts

Listen to podcasts

DOVATO (Dolutegravir/lamivudine)

DOVATO (Dolutegravir / lamivudine)

Dovato (dolutegravir/lamivudine) is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

Read more Prescribing information

VOCABRIA▼(Cabotegravir) + REKAMBYS▼(Rilpivirine)

Cabotegravir in combination with rilpivirine is indicated for treatment of HIV-1 in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior failure with, agents of NNRTI and INI class.

Read more Prescribing information

PM-GB-HVX-WCNT-220003 | November 2024

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.